Information date: 30 September 2026 — China regulates the collection, storage and outbound transfer of human genetic resources (HGR) and any international collaborative research using them. Foreign entities may not collect or store Chinese HGR domestically; foreign-sponsored trials involving sample collection, gene sequencing or biomarker testing must be filed or approved through a Chinese partner, and samples or data leaving the country need a separate exit approval. Review typically takes about 20 working days, extendable. Knowing that statement is not enough for an operating, research or compliance decision. The team must first establish who and what it applies to, how the effect reaches the real process, and which evidence would justify action.
Verified facts and scope
China regulates the collection, storage and outbound transfer of human genetic resources (HGR) and any international collaborative research using them. Foreign entities may not collect or store Chinese HGR domestically; foreign-sponsored trials involving sample collection, gene sequencing or biomarker testing must be filed or approved through a Chinese partner, and samples or data leaving the country need a separate exit approval. Review typically takes about 20 working days, extendable.
Applies to trials where a foreign sponsor, foreign-controlled entity or overseas lab takes part and Chinese participants' biosamples, sequencing data or derived information are involved. Confirm first: which partner is the domestic applicant, whether any foreign party can access raw data or results, whether samples or data cross the border, and whether the protocol is a listed international cooperation project.
How the effect reaches operations
The test is not the sponsor's nationality but whether a foreign party actually participates in and can obtain HGR information. A study that keeps samples onshore still falls under the rules if an overseas team reviews sequencing output or lab results, so the filing obligation follows data and material flows rather than shipping documents.
Common mistakes: assuming no export means no approval, routing work through a CRO or third-party lab without declaring the foreign link, using consent forms that do not cover overseas data sharing, and starting enrolment before approval or before a protocol amendment is filed. These expose the trial to suspension and the sponsor to penalties.
For “China Human Genetic Resources Approval: A Resource Checklist for Foreign-Sponsored Clinical Trials”, official rules or published findings, direct evidence from the relevant product or process, and assumptions that remain untested should be recorded separately. A broad source defines the external boundary; it does not replace batch records, protocols, contracts, labels or direct observations.
Decision
Run an eligibility screen before site activation: if a foreign party is involved and can access HGR data, file for approval first. If samples or data leave China, add the exit permit. Where the sponsor is unsure, request written confirmation from the domestic partner and the competent authority, and build one to three months of lead time into the plan.
Implementation checklist
- Screen every vendor and lab for foreign participation and data access.
- File HGR approval before the first participant is enrolled.
- Secure separate permits for any outbound sample or data transfer.
- Assign one decision owner, one implementation owner and a dated review point for “China Human Genetic Resources Approval: A Resource Checklist for Foreign-Sponsored Clinical Trials”.
- For “China Human Genetic Resources Approval: A Resource Checklist for Foreign-Sponsored Clinical Trials”, archive the source page, access date, applicable population or entity, and internal evidence both supporting and opposing the current decision.
- When a rule, formulation, supplier, protocol or observed result changes, reopen only the affected question in “China Human Genetic Resources Approval: A Resource Checklist for Foreign-Sponsored Clinical Trials”.
Evidence and review
For “China Human Genetic Resources Approval: A Resource Checklist for Foreign-Sponsored Clinical Trials”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Screen every vendor and lab for foreign participation and data access.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “File HGR approval before the first participant is enrolled.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Secure separate permits for any outbound sample or data transfer.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Limits of the conclusion
This checklist is not regulatory or legal advice; HGR review scope, competent authorities and timelines are updated periodically and should be confirmed with the current authority and PRC counsel.
